BCMA CAR T-cell therapy in a patient with heavily pretreated relapsed/refractory POEMS Syndrome: a case report
Annals of Hematology · 08.08.2026 · 105 (11)
DOI: 10.1007/s00277-026-07224-5 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 08.08.2026. Verfasst von Hongxiao Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing…. Hauptthemen laut MEDLINE: POEMS Syndrome, Immunotherapy, Adoptive, B-Cell Maturation Antigen, Receptors, Chimeric Antigen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T-cell) therapy is an established treatment for relapsed/refractory multiple myeloma. However, its application in POEMS syndrome remains largely unreported, despite overlapping pathogenesis involving plasma cell dyscrasia. Herein, we present a woman in her 30s with heavily pretreated relapsed/refractory POEMS syndrome who received equecabtagene autoleucel, a fully human anti-BCMA CAR T-cell product. The patient achieved a complete vascular endothelial growth factor (VEGF) response by day 14 post-infusion, with sustained remission through 12 months of follow-up. Clinical improvements included resolution of heart failure, pulmonary hypertension, and renal dysfunction, along with marked neurological recovery, enabling the patient to return to normal daily activities and occupational functioning, a status that persisted through the 16-month follow-up. Treatment-related toxicities comprised Grade 2 cytokine release syndrome and persistent hypogammaglobulinemia, without severe infectious complications. No delayed neurotoxicity or secondary malignancies were observed. This case provides evidence that BCMA CAR T-cell therapy is a safe and efficacious option for patients with relapsed/refractory POEMS syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Center for Rare Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. lijian@pumch.cn.
- Center for Rare Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. lijian@pumch.cn.
Förderung
- the National High Level Hospital Clinical Research Funding
Zitieren
APA
Han, H., Zhao, D., Li, A., Shen, K., Zhang, L., & Li, J. (2026). BCMA CAR T-cell therapy in a patient with heavily pretreated relapsed/refractory POEMS Syndrome: a case report. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07224-5
Vancouver
Han H, Zhao D, Li A, Shen K, Zhang L, Li J. BCMA CAR T-cell therapy in a patient with heavily pretreated relapsed/refractory POEMS Syndrome: a case report. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07224-5
BibTeX
@article{Han2026,
author = {Han, Hongxiao and Zhao, Danqing and Li, Anan and Shen, Kaini and Zhang, Lu and Li, Jian},
title = {BCMA CAR T-cell therapy in a patient with heavily pretreated relapsed/refractory POEMS Syndrome: a case report},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {11},
doi = {10.1007/s00277-026-07224-5}
}
EUVIMED